COVID-19 DNA vaccine development:
Announcement of Collaboration Agreement with Brickell Biotech

September 8, 2020, AnGes, Inc. (Head Office: Ibaraki City, Osaka; President and CEO: Ei Yamada) announced the Collaboration Agreement with Brickell Biotech, Inc. on DNA vaccine development for Novel Coronavirus (COVID-19). Since now on AnGes and Brickell Biotech search for the possibility of its clinical studies in the U.S. based on the agreement. AnGes is currently conducting Phase 1/2 clinical studies with its vaccine candidate in Japan, and the results from these studies will guide AnGes’ and Brickell’s global development efforts of this novel vaccine candidate.

“We are excited by the opportunity to work with AnGes, a leading vaccine developer in Japan, to potentially bring a COVID-19 vaccine to the U.S. and other countries to help address the global pandemic. AnGes is at the forefront of developing a vaccine for COVID-19 and was the first company in Japan to initiate a COVID-19 vaccine clinical study,” commented Robert Brown, Chief Executive Officer of Brickell. “While Brickell remains firmly focused on initiating its U.S. Phase 3 pivotal program for sofipironium bromide for the treatment of primary axillary hyperhidrosis later this year, we look forward to reviewing AnGes’ clinical study results and then working together with them and the FDA to determine the best path forward.

About Brickell Biotech
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s lead product candidate is sofipironium bromide, a novel and potential best-in-class treatment for primary axillary hyperhidrosis. The Company expects to initiate its U.S. Phase 3 pivotal program for sofipironium bromide in the fourth quarter of 2020. In addition, Brickell’s Japanese development partner for sofipironium bromide, Kaken Pharmaceutical Co., Ltd., expects to receive a regulatory decision for sofipironium bromide gel, 5% in Japan, later this year.

Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit http://www.brickellbio.com.

This is the minor impact on the full-year consolidated results for this fiscal year.